NCT02451293View on ClinicalTrials.gov

The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

January 18, 2016

Primary Completion Date

August 18, 2017

Study Completion Date

July 20, 2018

Conditions
DepressionAcute Coronary Syndrome
Interventions
DRUG

Melatonin (N-acetyl-5-methoxytryptamine)

DRUG

Placebo

Trial Locations (6)

2650

Department of Cardiology, Hvidovre Hospital,, Hvidovre

4000

Department of Cardiology, Roskilde Sygehus, Roskilde

4200

Department of Cardiology, Slagelse Sygehus, Slagelse

4300

Department of internal Medicin, Holbaek Sygehus, Holbæk

4600

Roskilde and Køge Hospital, Department of Surgery., Køge

Department of internal medicin, M5, Køge

Sponsors

Collaborators (1)

Pharma Nord
All Listed Sponsors
collaborator

Psychiatric Research Unit, Region Zealand, Denmark

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

Pharma Nord

INDUSTRY

lead

Zealand University Hospital

OTHER

NCT02451293 - The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome | Biotech Hunter | Biotech Hunter